UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 2, 2017

GALECTIN THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)

Nevada	**001-31791**	**04-3562325**
(State or Other Jurisdiction of Incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

4960 PEACHTREE INDUSTRIAL BOULEVARD, Ste 240
NORCROSS, GA 30071
(Address of principal executive office) (zip code)

Registrant's telephone number, including area code: (678) 620-3186

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SECTION 7 – REGULATION FD

Item 7.01 Regulation FD Disclosure.

On February 2, 2017, Galectin Therapeutics Inc. made a corporate presentation via VirtualInvestorConferences.com that contains, among other information, a summary of development of GR-MD-02 for Non-Alcoholic Steatohepatitis (NASH) With Advanced Fibrosis and Cirrhosis, which presentation is attached as Exhibit 99.1.

The information in this report is being furnished pursuant to this Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933 or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this report.

SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
99.1	Corporate presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Galectin Therapeutics Inc.

Date: February 2, 2017

By: /s/ Jack W. Callicutt
Jack W. Callicutt
Chief Financial Officer

Exhibit 99.1

Galectin Therapeutics

Corporate Presentation

February 2, 2017

NASDAQ: GALT

www.galectintherapeutics.com

Forward-Looking Statements

This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. These statements include those regarding potential therapeutic benefits of our drugs, expectations, plans and timelines related to our clinical trials, potential partnering opportunities and estimated spending for 2017. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, our trials may not lead to positive outcomes or regulatory approval. We may experience delays in our trials, which could include enrollment delays. Future phases or future clinical studies may not begin or produce positive results in a timely fashion, if at all, and could prove time consuming and costly. Plans regarding development, approval and marketing of any of our drugs are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. Strategies and spending projections may change. We may be unsuccessful in developing partnerships with other companies or obtaining capital that would allow us to complete our clinical trials or further develop and/or fund any future studies or trials. To date, we have incurred operating losses since our inception, and our future success may be impacted by our ability to manage costs and finance our continuing operations. For a discussion of additional factors impacting our business, see our Annual Report on Form 10-K for the year ended December 31, 2015, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

Galectin is a Development Phase Biotech Company with an Experienced Team

Peter G. Traber, M.D.
President,
CEO, CMO 
	Over 30 years relevant experience
	• **Recognized leader in gastroenterology and hepatology**
	• **University of Pennsylvania**
	  • **Chief of Gastroenterology**
	  • **Chairman of Internal Medicine**
	  • **CEO of Health System, Dean of Medicine**
	• **Baylor College of Medicine, President and CEO**
	• **GlaxoSmithKline, Senior Vice President and Chief Medical Officer**

Harold H. Shlevin, Ph.D. COO & Corporate Secretary	**Over 34 years of relevant experience** • **Solvay Pharmaceuticals, CEO** • **CIBA Vision Ophthalmics (n/k/a Novartis Vision), SVP & co-founder** • **Tikvah Therapeutics, Founder and CEO**
Jack W. Callicutt CFO	**Over 27 years of relevant experience; Reach Health, CFO, Vystar Corporation, CFO, Corautus Genetics, Deloitte**
Eli Zomer, PhD Pharm. Development	• **Over 34 years experience relevant experience; Koor Biotechnologies, Charm Sciences, Glycogenesis , HU Medical School (Jerusalem), Harvard University**
Adam Allgood, Pharm. D Clinical Development	• Over 28 years experience in regulatory affairs, clinical development and medical affairs; UCB Inc.; Abbott Laboratories; Solvay Pharmaceuticals
Rex Horton Regulatory	• **Over 26 years of experience; Director Regulatory Affairs at Solvay Pharmaceuticals and Chelsea Therapeutics; Georgia Institute of Technology.**

Developing Treatments for Diseases Where Galectin-3 Protein Is Implicated In Disease

Primary Program



NASH Cirrhosis

Combination Immunotherapy

Psoriasis
Atopic Dermatitis

Galectin-3





Promising Anti-Galectin Lead Drug

- **GR-MD-02 is a complex carbohydrate drug that binds to and disrupts galectin-3 function**
- **Existing patent coverage through 2031 with multiple US and international patents issued**
- **Broad activity in galectin-dependent animal models of disease; *effect on immune system mechanisms***
- **Excellent safety after over 2,500 human drug doses**
- **Robust activity in human disease: Moderate-to-severe plaque psoriasis**
- **Promising treatment for lead indication of NASH cirrhosis**

Overall Strategy: Targeting Galectin-3 Is A Platform Technology For Multiple Diseases

Psoriasis
Atopic Dermatitis

Proof of clinical efficacy in a human disease

Primary Program



Fatty Liver Disease
NASH Cirrhosis

Future Possible Indications

Disease Indications	Supportive Work By GALT
Fibrosis in Lung, Kidney, Heart and Blood Vessels	Positive data in animal models for all
Cancer	Effective in animal models; ongoing clinical studies

Large And Unmet Medical Need

Fatty Liver Disease (NASH) is Global Epidemic

- 1/4 people in the world are affected by fatty liver disease[1]
- Life-time risk of ~20 million liver-related deaths among fatty liver disease patients currently alive[1]
- Global annual market could be $35-40 Billion by 2025[2]
- Recent acquisitions confirm NASH opportunity (Tobira acquired by Allergan for $1.7 billion)

[1] Rinella M, Charlton M. The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health. Hepatology 2016 Jul;64(1):19-22

[2] Who will be the kings of NASH-ville? Key players and an overview. May 21, 2015, Alethia Young, Deutsche Bank Markets Research

Clinical Progression Of Fatty Liver Disease*



*Rinella M, Charlton M. The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health. Hepatology 2016 Jul;64(1):19-22

Galectin Therapeutics Is Targeting The Stage Of Fibrosis That Increases Mortality



Many companies focused on pre-cirrhotic NASH

Galectin is the only company with active Phase 2 trial in NASH cirrhosis

Disease Stage in NASH Treatment

- Fatty liver disease progresses slowly and is asymptomatic until cirrhosis develops
- Early stages of NASH are difficult to diagnose and one cannot determine which patients will eventually progress to cirrhosis
- In the early stages of disease, lifestyle changes (weight loss and exercise) are effective in reversing NASH (fat, inflammation, and cell death) and mild degrees of fibrosis
- The majority of patients with fatty liver will likely never reach cirrhosis or have liver-related problems
- If early stages of NASH are targeted for therapy, millions of people will be treated for a liver disorder that was not going to threaten their lives

Significance of Targeting NASH Cirrhosis

- **Once NASH progresses to cirrhosis, patients are at risk for severe complications, liver failure, and death**
- **The only currently available therapy for NASH cirrhosis is liver transplant when clinical progression is severe**
- **Once NASH progresses to cirrhosis it is not reversible with lifestyle changes alone**
- **Goal of GR-MD-02 is to *Reduce Fibrosis*, leading to improved liver function and positively affect patient outcomes**
- **Galectin is the only company with currently active Phase 2 NASH cirrhosis trial**

Fundamental Science On Target Is Strong:
Galectin-3 Is Critically Important In The Development Of Organ Fibrosis

- **Galectin-3 null mice (no galectin-3) are resistant to fibrosis due to toxin-induced liver toxicity**

Red stain is collagen, the principal component of fibrotic tissue

Mice treated with liver toxin to induce fibrosis



Normal mice develop fibrosis whereas those without gal-3 do not

Henderson, et al 2006

- **Galectin-3 null mice are also resistant to fibrosis in:**
  - Fatty liver disease
  - Kidney fibrotic disease
  - Lung fibrotic disease
  - Cardiovascular disease

GR-MD-02 Reversed Cirrhosis In Thioacetamide-Treated Rat Model*

Vehicle-Treated



GR-MD-02-Treated (Four weekly infusions)



Collagen



Portal Pressure



*Traber PG, Chou H, Zomer E, Hong F, Klyosov A Fiel M-I, Friedman, SL. Therapy of Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLOS ONE 2013;8:e75361.

Preclinical Data Shows That GR-MD-02 Can Reverse NASH, Fibrosis, And Cirrhosis

Effect	NASH mouse[1]	Cirrhotic rat[2]
Reduces inflammation	X	X
Reduces fat	X	N/A
Reduces cell death	X	X
Prevents fibrosis	X	X
Reverses fibrosis	X	X
Reduces portal pressure	N/A	X
Targets macrophages in liver	X	X
Reduces galectin-3 in liver	X	X

N/A = not applicable

Peer-reviewed publications:

[1]*Traber PG and Zomer E. Therapy of Experimental NASH and Fibrosis with Galectin Inhibitors. PLOS ONE 2013;8:e83481*

[2]*Traber PG, Chou H, Zomer E, Hong F, Klyosov A Fiel M-I, Friedman, SL. Therapy of Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLOS ONE 2013;8:e75361.*

Early Clinical Trial Experience Demonstrates GR-MD-02 Is Safe And Well Tolerated

- Fast Track designation from FDA
- Phase 1 study in normal volunteers was safe and did not cross-react with commonly used drug
- Phase 1 study in NASH patients with advanced fibrosis showed GR-MD-02 was safe and well tolerated and reached targeted doses
- Promising Phase 1 data was followed by a short-treatment phase, exploratory Phase 2a study (NASH-FX)
  - 30 patients (15 placebo, 15 GR-MD-02 (8 mg/kg)) received 4 months of therapy
  - No significant improvements in non-invasive testing
  - Drug was safe and well-tolerated
- Total clinical trial experience: Over 2,500 drug doses have been administered without serious adverse effects related to the drug

NASH-CX Phase 2b Clinical Trial

- ***Intended lead market indication: NASH Cirrhosis***



- **Enrollment completed with 162 patients at 36 U.S. sites**
- **Three treatment arms:**
  - **Placebo, 2 mg/kg GR-MD-02, and 8 mg/kg GR-MD-02**
  - **Every other week infusions for 52 weeks**

For more information see clinicaltrials.gov

NASH-CX Phase 2b Clinical Trial

- **Enrolled Patients**
  - NASH cirrhosis with portal hypertension
  - Well compensated disease with no complications of cirrhosis
- **Primary Endpoint**
  - Portal pressure (HVPG—hepatic venous pressure gradient)
  - Change in baseline adjusted HVPG from beginning to end of study
  - FDA views this endpoint as a potentially acceptable surrogate for outcomes for registration trials in this patient population.
- **Secondary Endpoints**
  - Liver biopsy for staging of fibrosis
  - FibroScan® for measuring liver stiffness which is related to fibrosis
  - Methacetin breath test which measures liver function
  - Patient outcomes
- **Independent data safety monitoring board (DSMB) found no safety concerns after evaluating 50% of subjects completing 6 months of therapy**

For more information see clinicaltrials.gov

NASH-CX Phase 2b Clinical Trial: Status as of February 2017

- Completed enrollment with 162 total patients
- 47 patients have completed all 52 weeks of infusions and 122 patients have completed 26 weeks of infusions
- 75% of the total number of infusions in the entire study delivered
- On track to report top line data in December 2017
- Company funded through the end of 2017, which is sufficient to report top line data of NASH-CX
- A drug that can halt progression of, or reverse existing fibrosis, in NASH cirrhosis patients would be a breakthrough therapeutic intervention that may prevent complications, alleviate the need for liver transplant, and even prevent death.

Overall Strategy: Targeting Galectin-3 Is A Platform Technology For Multiple Diseases

Psoriasis
Atopic Dermatitis

Proof of clinical efficacy in a human disease

Primary Program



Fatty Liver Disease
NASH Cirrhosis

Out licensing opportunity

Activity of GR-MD-02 In Moderate-to-Severe Plaque Psoriasis

- **Psoriasis is immune-mediated chronic skin inflammation associated with NASH. One patient treated with GR-MD-02 in NASH Phase 1 trial had long-term remission of psoriasis**
- **All 5 patients treated in Phase 2a open label trial showed improvement in disease activity by an average of 50%. One patient improved by 82%**



GR-MD-02 Has Efficacy In Moderate-To-Severe Plaque Psoriasis



PASI = Psoriasis area & severity score

Investigator-Initiated Study For Patients With Severe Atopic Dermatitis (AD)

- **AD is a chronic pruritic (itching), immune-mediated, inflammatory skin disease that for some adult patients can be severe and debilitating**
- **Important unmet medical need in adults with severe disease who are not adequately treated with topical medicines**
- **Open label trial initiated in three adult patients**
  - Treated with GR-MD-02 at 8 mg/kg every other week for 12 weeks
  - Increased to 12 mg/kg for weeks 12 through 24 if incomplete response
- **Objective evaluation of response to therapy are validated scores**
  - The eczema area and severity index (EASI)
  - The severity scoring of atopic dermatitis index (SCORAD)

GR-MD-02 Study in Severe Atopic Dermatitis
Positive Interim Results

Patient	Baseline EASI SCORAD	Week 6 EASI (% Δ) SCORAD (% Δ)	Week 12 EASI (% Δ) SCORAD (% Δ)	Week 18 EASI (% Δ) SCORAD (% Δ)
1*	39.55 67.6	14 (-65%) 30 (-56%)	15.9 (-60%) 33.1 (-51%)	11.6 (-71%) 29 (-57%)
2	31.7 67	22.8 (-28%) 52.5 (-22%)	N/A**	N/A
3	15.2 47	4 (-74%) 27 (-43%)	N/A	N/A

EASI = eczema area and severity index
SCORAD = severity scoring of atopic dermatitis index
* Dose increased to 12 mg/kg after day 84
** N/A patient has not reached time point in study

Early in the course of this 24 week study, all three patients have shown clinically significant improvements

Next Steps For Severe Skin Diseases

- **Moderate-to-severe plaque psoriasis**
  - There are currently multiple effective biological agents on the market
  - All biologics have some degree of serious side effects and are expensive
  - Potential market for GR-MD-02 if focused on a safe and less expensive alternative that may be used in specific situations
- **Severe atopic dermatitis**
  - Currently no approved biologicals, but one agent showed efficacy in phase 3 and is pending approval (duplimumab).
  - Potential market opportunity in this area
- **Galectin engaged in seeking a partner to advance the skin disease indications**

Overall Strategy: Targeting Galectin-3 Is A Platform Technology For Multiple Diseases

Psoriasis
Atopic Dermatitis

Proof of clinical efficacy in a human disease

Primary Program



NASH Cirrhosis

Out licensing opportunity

Future Possible Indications

Disease Indications	Supportive Work By GALT
Fibrosis in Lung, Kidney, Heart and Blood Vessels	Positive data in animal models for all
Cancer	Effective in animal models; ongoing clinical studies

Cancer Immunotherapy

Focus on Immunotherapy	• Galectin-3 secreted by cancer cells into the tumor microenvironment reduces the ability of immune system to fight cancer
Market Opportunity	• Even with newly approved drugs, a substantial unmet medical need remains in melanoma and multiple other cancers
Critical Collaboration Established	• Providence Cancer Center in Portland, Oregon • Performed preclinical studies showing efficacy of GR-MD-02 with checkpoint inhibitors • Conducting and funding two P1b clinical trials

Combination Cancer Immunotherapy

- **Combination P1b trials conducted at Providence Cancer Center**
  - Advanced Melanoma: GR-MD-02 In Combination With Yervoy®
  - Advanced Melanoma: GR-MD-02 In Combination With KEYTRUDA®
  - KEYTRUDA trial expanded to include head and neck and lung cancer
  - Study details on clinicaltrials.gov
- **Preliminary data report February 2017**
  - ***Venue:*** GTCbio 9th Immunotherapeutics & Immunomonitoring Conference, to be held on February 6-7, 2017, in San Diego, California
  - ***Presenter:*** Dr. Will Redmond, Providence Cancer Center, Portland, OR
  - ***Title of presentation:*** "The combination of immunotherapy plus galectin-3 inhibition with GR-MD-02 improves anti-tumor immunity and survival: Insights from mice and a first-in-human phase I clinical trial"

Summary of Anti-Galectin Therapy Program With GR-MD-02

- Novel antigalectin-3 drug compound that can modulate immune system and may improve multiple diseases
  - Strong patent portfolio and extensive pre-clinical and early clinical data demonstrates strong safety profile and tolerability
- Lead indication of NASH Cirrhosis is an unmet medical need with large potential market and we are competitively well positioned
  - Reversal of fibrosis/cirrhosis in preclinical models
  - Phase 2b clinical trial with potential registration endpoints fully enrolled with readout December 2017
- Clinically significant effect in severe, immune related skin diseases; immune mechanisms in NASH
- Potential platform technology for use in cancer immunotherapy and other fibrotic indications

Thank you!



Easily accessible, in depth information on programs:
http://perspectives.galectintherapeutics.com/

CEO PERSPECTIVES with Peter G. Traber, M.D.